{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:18:16Z","timestamp":1791332296540,"version":"4.3.1"},"reference-count":45,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"unspecified","delay-in-days":239,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08082, 25K10874"],"award-info":[{"award-number":["19K08082, 25K10874"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Psychol. Med."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S0033291725101578_sec1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal duration for maintaining antidepressant treatment in individuals with obsessive-compulsive disorder (OCD) who achieve symptom stabilization remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0033291725101578_sec2\" sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and pairwise meta-analysis of double-blind randomized placebo-controlled trials (DBRPCTs) compared antidepressant maintenance and antidepressant discontinuation groups in terms of relapse rate at each DBRPCT study endpoint (primary outcome), OCD symptom improvement, all-cause discontinuation, and adverse event-related discontinuation. Furthermore, relapse rates at 4, 8, 12, 16, 20, and 24\u00a0weeks were compared between the groups. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. The absolute risk reduction (ARR) and number needed to treat to benefit (NNTB) for relapse rates were also estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0033291725101578_sec3\" sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine trials (n\u00a0=\u00a01084; mean age: 32.8\u00a0years; proportion of males: 53.3%) were included. The antidepressant maintenance group had lower relapse rates at each DBRPCT study endpoint (RR [95% CI]\u00a0=\u00a00.53 [0.42\u20130.68]; ARR\u00a0=\u00a021.0%; NNTB\u00a0=\u00a05) and lower all-cause and adverse event-related discontinuation rates than the antidepressant discontinuation group. The maintenance group also exhibited lower relapse rates at 4 weeks (RR [95% CI]\u00a0=\u00a00.47 [0.31\u20130.70]; ARR: not significant; NNTB: not significant), 8\u00a0weeks (0.42 [0.31\u20130.57]; 12.0%; 8), 12\u00a0weeks (0.43 [0.32\u20130.56]; 18.0%; 6), 16\u00a0weeks (0.41 [0.32\u20130.52]; 25.0%; 4), 20\u00a0weeks (0.43 [0.34\u20130.53]; 26.0%; 4), and 24\u00a0weeks (0.42 [0.33\u20130.52]; 27.0%; 4) than the discontinuation group. Moreover, the maintenance group outperformed the discontinuation group regarding OCD symptom improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0033291725101578_sec4\" sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Individuals with OCD may benefit from continued antidepressant treatment, provided that it is well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s0033291725101578","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:03:05Z","timestamp":1756371785000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":5,"title":["Relapse rates in stable obsessive-compulsive disorder after antidepressant discontinuation versus maintenance: A systematic review and meta-analysis"],"prefix":"10.1017","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-2236","authenticated-orcid":false,"given":"Taro","family":"Kishi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046f6cx68","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujita Health University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046f6cx68","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujita Health University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Hatano","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046f6cx68","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujita Health University School of Medicine"},{"id":[{"id":"https:\/\/ror.org\/046f6cx68","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujita Health University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Hamanaka","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046f6cx68","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujita Health University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Nishii","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046f6cx68","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujita Health University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046f6cx68","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujita Health University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"S0033291725101578_r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2023.152371"},{"key":"S0033291725101578_r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.06.021"},{"key":"S0033291725101578_r5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13185358"},{"key":"S0033291725101578_r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2022.152339"},{"key":"S0033291725101578_r40","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200102000-00009"},{"key":"S0033291725101578_r6","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"S0033291725101578_r43","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0102-3"},{"key":"S0033291725101578_r4","first-page":"146","article-title":"Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: Pharmacological treatment","volume":"45","author":"de Oliveira","year":"2023","journal-title":"Brazilian Journal of Psychiatry"},{"key":"S0033291725101578_r2","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2022.2086296"},{"key":"S0033291725101578_r8","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision","year":"2022"},{"key":"S0033291725101578_r18","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"S0033291725101578_r39","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000548"},{"key":"S0033291725101578_r42","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30069-4"},{"key":"S0033291725101578_r32","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.1.88"},{"key":"S0033291725101578_r35","unstructured":"NCT00215137. (2009). Pilot study to evaluate escitalopram in obsessive-compulsive disorder. https:\/\/clinicaltrials.gov\/study\/NCT00215137?term=NCT00215137&rank=1&tab=results"},{"key":"S0033291725101578_r44","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2022.2082525"},{"key":"S0033291725101578_r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111147"},{"key":"S0033291725101578_r24","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00946-6"},{"key":"S0033291725101578_r16","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110048007"},{"key":"S0033291725101578_r22","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0919"},{"key":"S0033291725101578_r26","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13622"},{"key":"S0033291725101578_r17","unstructured":"GSK. (1994). Long-term treatment with paroxetine of outpatients with obsessive-compulsive disorder: An extension of the companion study (MY-1053\/BRL-029060\/CPMS-127). https:\/\/s3.amazonaws.com\/ctr-gsk-7381\/29060_127\/d3d3dc00-f63f-4f71-adc9-eb4eecbe69bd\/e9901ff2-9022-4668-8b11-6ce411a7b514\/2072-v1.pdf"},{"key":"S0033291725101578_r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.12.003"},{"key":"S0033291725101578_r9","first-page":"321","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"S0033291725101578_r37","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"S0033291725101578_r25","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01334-4"},{"key":"S0033291725101578_r33","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X16666181026163922"},{"key":"S0033291725101578_r15","doi-asserted-by":"publisher","DOI":"10.1089\/104454603322126313"},{"key":"S0033291725101578_r1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114525674"},{"key":"S0033291725101578_r34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"S0033291725101578_r36","unstructured":"NICE. (2005). Treating obsessivecompulsive disorder (OCD) and body dysmorphic disorder (BDD) in adults, children and young people. National Institute for Health and Clinical Excellence. https:\/\/www.nice.org.uk\/guidance\/cg31\/resources\/treating-obsessivecompulsive-disorder-ocd-and-body-dysmorphic-disorder-bdd-in-adults-children-and-young-people-pdf-194882077"},{"key":"S0033291725101578_r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2006.11.005"},{"key":"S0033291725101578_r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.11.001"},{"key":"S0033291725101578_r23","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.196976"},{"key":"S0033291725101578_r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2020.08.003"},{"key":"S0033291725101578_r41","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199706000-00023"},{"key":"S0033291725101578_r27","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01824-z"},{"key":"S0033291725101578_r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.3997"},{"key":"S0033291725101578_r20","unstructured":"Higgins, J. , Thomas, J. , Chandler, J. , Cumpston, M. , Li, T. , Page, M. , & Welch, V. (2022). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). www.training.cochrane.org\/handbook"},{"key":"S0033291725101578_r29","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01920-0"},{"key":"S0033291725101578_r31","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0415"},{"key":"S0033291725101578_r3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3927"},{"key":"S0033291725101578_r21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.2200"},{"key":"S0033291725101578_r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2022.10.003"},{"key":"S0033291725101578_r30","unstructured":"Koran, L. , & Simpson, H. (2013). Practice guideline for the treatment of patients with obsessive-compulsive disorder. APA March 2013. https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/ocd-watch-1410457187510.pdf"}],"container-title":["Psychological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0033291725101578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:03:08Z","timestamp":1756371788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0033291725101578\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":45,"alternative-id":["S0033291725101578"],"URL":"https:\/\/doi.org\/10.1017\/s0033291725101578","relation":{},"ISSN":["0033-2917","1469-8978"],"issn-type":[{"value":"0033-2917","type":"print"},{"value":"1469-8978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e252"}}